Form 8-K - Current report:
SEC Accession No. 0001104659-25-011851
Filing Date
2025-02-12
Accepted
2025-02-12 08:06:00
Documents
14
Period of Report
2025-02-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm256243d1_8k.htm   iXBRL 8-K 26389
2 EXHIBIT 99.1 tm256243d1_ex99-1.htm EX-99.1 64131
  Complete submission text file 0001104659-25-011851.txt   272566

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA repl-20250212.xsd EX-101.SCH 3018
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE repl-20250212_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE repl-20250212_pre.xml EX-101.PRE 22361
16 EXTRACTED XBRL INSTANCE DOCUMENT tm256243d1_8k_htm.xml XML 3683
Mailing Address 500 UNICORN PARK WOBURN MA 01801
Business Address 500 UNICORN PARK WOBURN MA 01801 (781) 222-9600
Replimune Group, Inc. (Filer) CIK: 0001737953 (see all company filings)

EIN.: 822082553 | State of Incorp.: DE | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-38596 | Film No.: 25612080
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)